GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Santhera Pharmaceuticals Holding AG (OTCPK:SPHDF) » Definitions » Revenue

Santhera Pharmaceuticals Holding AG (Santhera Pharmaceuticals Holding AG) Revenue : $5.69 Mil (TTM As of Jun. 2023)


View and export this data going back to 2008. Start your Free Trial

What is Santhera Pharmaceuticals Holding AG Revenue?

Santhera Pharmaceuticals Holding AG's revenue for the six months ended in Jun. 2023 was $4.38 Mil. Its revenue for the trailing twelve months (TTM) ended in Jun. 2023 was $5.69 Mil. Santhera Pharmaceuticals Holding AG's Revenue per Share for the six months ended in Jun. 2023 was $0.39. Its Revenue per Share for the trailing twelve months (TTM) ended in Jun. 2023 was $0.59.

Warning Sign:

Santhera Pharmaceuticals Holding AG revenue per share has been in decline over the past 3 years.

During the past 3 years, the average Revenue per Share Growth Rate was -73.90% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get other companies' revenue growth rate using Revenue per Share data.

During the past 13 years, Santhera Pharmaceuticals Holding AG's highest 3-Year average Revenue per Share Growth Rate was 288.30% per year. The lowest was -73.90% per year. And the median was 12.40% per year.


Santhera Pharmaceuticals Holding AG Revenue Historical Data

The historical data trend for Santhera Pharmaceuticals Holding AG's Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Santhera Pharmaceuticals Holding AG Revenue Chart

Santhera Pharmaceuticals Holding AG Annual Data
Trend Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
Revenue
Get a 7-Day Free Trial Premium Member Only Premium Member Only 31.92 76.71 16.89 -1.73 8.02

Santhera Pharmaceuticals Holding AG Semi-Annual Data
Dec13 Jun14 Dec14 Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23
Revenue Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 4.95 -6.61 6.44 1.31 4.38

Competitive Comparison of Santhera Pharmaceuticals Holding AG's Revenue

For the Biotechnology subindustry, Santhera Pharmaceuticals Holding AG's Revenue, along with its competitors' market caps and Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Santhera Pharmaceuticals Holding AG's Revenue Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Santhera Pharmaceuticals Holding AG's Revenue distribution charts can be found below:

* The bar in red indicates where Santhera Pharmaceuticals Holding AG's Revenue falls into.



Santhera Pharmaceuticals Holding AG Revenue Calculation

Also referred as sales, revenue is income that a company receives from its normal business activities, usually from the sale of goods and services to customers. Revenue is often referred to as the "top line" due to its position on the income statement at the very top.

Revenue for the trailing twelve months (TTM) ended in Jun. 2023 adds up the semi-annually data reported by the company within the most recent 12 months, which was $5.69 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Santhera Pharmaceuticals Holding AG  (OTCPK:SPHDF) Revenue Explanation

In ranking the predictability, companies with more consistent revenue and earnings growth are ranked high with predictability.

Peter Lynch categorized companies according to their revenue growth:


Slow Grower: Inflation < 10-Year Revenue Growth Rate < 10%:
Stalwart: 10% < 10-Year Revenue Growth Rate < 20%:
Fast Grower: 10-Year Revenue Growth Rate > 20%:

His favorite companies are stalwart, those growing between 10-20% a year.

Companies in cyclical industries may see their revenue fluctuate wildly in good years and bad years.


Be Aware

Revenue can be manipulated by changing the way how revenue is booked. Companies may book sales before the payment is received, or before the revenue is fully earned. These will be added to balance sheet items such as account payable or account receivables.


Santhera Pharmaceuticals Holding AG Revenue Related Terms

Thank you for viewing the detailed overview of Santhera Pharmaceuticals Holding AG's Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.


Santhera Pharmaceuticals Holding AG (Santhera Pharmaceuticals Holding AG) Business Description

Traded in Other Exchanges
Address
Hohenrainstrasse 24, Pratteln, CHE, 4133
Santhera Pharmaceuticals Holding AG is a specialty pharmaceutical company focused on the development and commercialization of products for the treatment of mitochondrial and neuromuscular diseases, an area that includes many orphan and niche indications with high unmet medical needs. It has one operating segment, namely the development and commercialization of products for the treatment of neuro-ophthalmological, pulmonary, and neuromuscular diseases. The company derives most of its revenue from the European Union.